CD19 and acute lymphoblastic leukemia: Compared to our previous data using the combination of free 17-DMAG and imatinib, the CD19-targeted nanoparticle delivery system with imatinib significantly reduced disease burden and improved survival in a murine model of BCR-ABL1+ B-ALL (Figure 4).